Gelesis is a biotechnology company developing a novel category of potential therapies for GI-related chronic diseases including obesity, NAFLD/NASH, IBD and type 2 diabetes by targeting the natural processes of the GI pathway. Utilizing our novel hydrogel platform technology and the emerging science of mechanobiology, we are developing innovative approaches to target the cause of those epidemics rather than just improving thei...
Gelesis is a biotechnology company developing a novel category of potential therapies for GI-related chronic diseases including obesity, NAFLD/NASH, IBD and type 2 diabetes by targeting the natural processes of the GI pathway. Utilizing our novel hydrogel platform technology and the emerging science of mechanobiology, we are developing innovative approaches to target the cause of those epidemics rather than just improving their symptoms. Our first-in-class products are designed to trigger multiple mechanisms throughout the GI system related to satiety, glycemic control, gut permeability and inflammation.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.